Back to Search
HASSANE ZAROUR, MD
MD
Specialist
NPI: 1710953989IndividualAccepts Medicare
Specialties, Licenses & Credentials
SpecialistPrimary
Specialist
Code: 174400000X
MD425423(PA)
CMS Specialties
PrimaryDERMATOLOGY
Education
OTHER
Class of 1991
Research & Publications (20)
Melanoma vaccines: early progress and future promises.
PMID 12773015·Semin Cutan Med Surg·2003
6-review
NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells.
PMID 11782380·Cancer Res·2002
8-other
NY-ESO-1 encodes DRB1*0401-restricted epitopes recognized by melanoma-reactive CD4+ T cells.
PMID 10987311·Cancer Res·2000
8-other
Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells.
PMID 10618430·Proc Natl Acad Sci U S A·2000
8-other
Randomized phase 2/3 trial of CpG oligodeoxynucleotide PF-3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma.
PMID 19536884·Cancer·2009
3-trial
PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients.
PMID 19380770·J Immunol·2009
8-other
Immunization with analog peptide in combination with CpG and montanide expands tumor antigen-specific CD8+ T cells in melanoma patients.
PMID 18779741·J Immunother·2008
3-trial
Cross-reactive CD4+ T cells against one immunodominant tumor-derived epitope in melanoma patients.
PMID 18025241·J Immunol·2007
8-other
Inhibition of cytokine production and cytotoxic activity of human antimelanoma specific CD8+ and CD4+ T lymphocytes by adenosine-protein kinase A type I signaling.
PMID 17575165·Cancer Res·2007
8-other
Differential capacity of T cell priming in naive donors of promiscuous CD4+ T cell epitopes of HCV NS3 and Core proteins.
PMID 17492804·Eur J Immunol·2007
7-preclinical
Selective identification of HLA-DP4 binding T cell epitopes encoded by the MAGE-A gene family.
PMID 16988823·Cancer Immunol Immunother·2007
7-preclinical
Spontaneous CD4+ T cell responses against TRAG-3 in patients with melanoma and breast cancers.
PMID 16888034·J Immunol·2006
7-preclinical
One NY-ESO-1-derived epitope that promiscuously binds to multiple HLA-DR and HLA-DP4 molecules and stimulates autologous CD4+ T cells from patients with NY-ESO-1-expressing melanoma.
PMID 15661941·J Immunol·2005
8-other
The alternative open reading frame of LAGE-1 gives rise to multiple promiscuous HLA-DR-restricted epitopes recognized by T-helper 1-type tumor-reactive CD4+ T cells.
PMID 14559844·Cancer Res·2003
8-other
HLA-DP4, the most frequent HLA II molecule, defines a new supertype of peptide-binding specificity.
PMID 12471126·J Immunol·2002
8-other
Immunomodulatory effects of high-dose and low-dose interferon alpha2b in patients with high-risk resected melanoma: the E2690 laboratory corollary of intergroup adjuvant trial E1690.
PMID 12209697·Cancer·2002
3-trial
Absence of gamma-interferon-inducible lysosomal thiol reductase in melanomas disrupts T cell recognition of select immunodominant epitopes.
PMID 12021307·J Exp Med·2002
8-other
Mature dendritic cells pulsed with freeze-thaw cell lysates define an effective in vitro vaccine designed to elicit EBV-specific CD4(+) and CD8(+) T lymphocyte responses.
PMID 10961887·Blood·2000
8-other
Dendritic cell/peptide cancer vaccines: clinical responsiveness and epitope spreading.
PMID 10854179·Immunol Invest·2000
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 5115 CENTRE AVE
PITTSBURGH, PA 15232 - Phone
- (412) 692-4724
Quick Facts
- NPI
- 1710953989
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 35
- Publications
- 20
Are you this provider?
Claim Your Profile